Tretinoin Patent Expiration
Tretinoin was first introduced by Valeant International Barbados Srl
Tretinoin Patents
Given below is the list of patents protecting Tretinoin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Altreno | US10653656 | Topical pharmaceutical compositions for treating skin conditions | Aug 22, 2038 | Dow Pharm |
| Altreno | US11324710 | Topical pharmaceutical compositions for treating skin conditions | Aug 22, 2038 | Dow Pharm |
| Altreno | US6517847 | Topical gel delivery system |
Aug 03, 2020
(Expired) | Dow Pharm |
| Renova | US6531141 | Oil-in-water emulsion containing tretinoin |
Mar 07, 2020
(Expired) | Valeant Pharms North |
| Retin-a Micro | US5955109 | Methods and compositions for topical delivery of retinoic acid |
Sep 21, 2016
(Expired) | Bausch |
| Retin-a-micro | US5955109 | Methods and compositions for topical delivery of retinoic acid |
Sep 21, 2016
(Expired) | Bausch |
| Atralin | US5670547 | Moisturizing vehicle for topical application of vitamin A acid |
Sep 23, 2014
(Expired) | Dow Pharm |
Tretinoin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Tretinoin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | Dwight Owen | NA |
COMPLETED
(Jul 1, 2026)
| PHASE1 |
| A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris | Sun Pharmaceutical Industries, Inc. | NA |
COMPLETED
(Mar 1, 2026)
| PHASE1 |